分子剂可以抑制二基酶活性和炎症信号传递
Francesca Chandler1, Poli Adi Narayana Reddy2, Smita Bhutda3
1Astbury Centre for Structural Molecular Biology, School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, UK.
bioRxiv : the preprint server for biology
|September 16, 2024
概括
研究人员开发了新的BRISC分子剂 (BLUEs),通过稳定其二次体来选择性抑制BRISC复合物. 这种方法为治疗I型干扰素介导疾病提供了新的策略.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
背景情况:
- 脱多样性激酶 (DUB) 是细胞信号的关键调节者,通常由蛋白质复杂相互作用控制.
- BRCC36异酶复合体 (BRISC) 通过从I型干扰素受体 (IFNAR1) 中去除K63结合的多基因链来调节炎症信号传递.
- 针对BRCC36等Zn2+-依赖的JAMM/MPN DUB,使用选择性抑制剂是具有挑战性的,因为它们的复杂性质.
研究的目的:
- 发现和描述BRISC复合体的第一类抑制剂.
- 通过稳定蛋白质-蛋白质相互作用来研究DUB抑制的新机制.
- 探索BRISC抑制在I型干扰素介导疾病中的治疗潜力.
主要方法:
- 发现了稳定BRISC复合物的BRISC分子粘剂 (BLUEs).
- 生物化学测试以评估DUB活动和选择性.
- 基于细胞的测试来评估BLUE对干扰素信号通路的影响.
- 使用结构引导的,抗抑制剂的突变体来确认作用机制.
主要成果:
- 蓝色稳定一个16个子单元的BRISC二元体在一个自抑制的形状,选择性地阻断活跃的网站.
- 抑制是BRISC特有的,节省相关复合体,拼接变体和其他JAMM/MPN DUBs.
- 蓝色治疗减少了干扰素刺激的基因表达,并通过增加其无处不在来降低IFNAR1的细胞表面水平.
结论:
- 蓝色代表了一类新的DUB抑制剂,具有独特的作用机制.
- 用蓝色准BRISC为I型干扰素相关疾病提供了潜在的治疗策略.
- 这种方法提供了一个框架,通过调节蛋白质-蛋白质相互作用来开发大型蛋白质复合物的选择性抑制剂.
相关概念视频
Receptor Downregulation in MVBs
2.0K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.0K
Covalently Linked Protein Regulators
6.8K
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
These groups modify specific amino acids in a protein....
6.8K
Regulated Protein Degradation
7.2K
It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
7.2K
The JAK-STAT Signaling Pathway
8.7K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.7K
TGF - β Signaling Pathway
7.3K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.3K
Amplifying Signals via Enzymatic Cascade
8.4K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
8.4K


